Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2005-06-17
2010-11-02
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C514S567000
Reexamination Certificate
active
07824697
ABSTRACT:
Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.
REFERENCES:
patent: 5149713 (1992-09-01), Bousquet
patent: 2004/0062819 (2004-04-01), Hildebrand
Physicians' Desk Reference, (Lioresal® Intrathecal, 1995, Medical Economics Data Production Company, 49th edition, 1487-1489.
Baum, S. and Schuster, F., “Production and Testing of Baclofen Solutions,” Pharmazeutische Zeitung, vol. 133, Germany, pp. 28-32 (1988).
Diogenes Record No. 2905396, MDR Report: Neurological Division, Medtronic, Inc. Indura LKK, Model #8731 (2008).
Diogenes Record No. 2779300, MDR Report: Medtronic, Inc. Synchromed B Pump, Intrathecal, Model #8267 (2007).
Diogenes Record No. 2596683, MDR Report: Rice Creek Manufacturing Indura Catheter, Model #8709 (2006).
Ridley, B. and Rawlins, P., “Intrathecal Baclofen Therapy: Ten Steps Toward Best Practice,” Journal of Neuroscience Nursing: 38:2, pp. 72-82 (2006).
International Search Report dated Sep. 5, 2005.
Ahuja S., “Baclofen,”Analytical Profiles of Drug Substances,vol. 14, New York: Academic Press, pp. 527-548, 1985.
Allen L. V., et al., “Stability of Baclofen, Captopril, Diltiazem Hydrochloride, Dipyridamole, and Flecainide Acetate is Extemporaneously Compounded Oral Liquids”,Am J Health-Syst. Pharm.,53:2179-2184, 1996.
Cruaud et al., “The Characterization and Release Kinetics Evaluation of Baclofen Microspheres Designed for Intrathecal Injection”,Int. J. Pharmacuetics,177, 247-257), 1999.
Gupta V. D., Parasrampuria J., “Quantitation of 4-(4-chlorophenyl)-2-pyrrolidine in baclofen powder and tablets,”Drug Develop. Indust. Pharm.,14: 1623-1628, 1998.
Holloway, R. H., “Systemic Pharmacomodulation of Transient Lower Esophageal Sphincter Relations,”Amer. J. Medicine,111:8A, 178S-185S, 2001.
Johnson C. E., et al., “Stablility of an extemporaneously compounded baclofen oral liquid”,Am. J. Hosp. Pharm.,50:2353-55, 1993.
Lioresal Intrathecal package insert, Medtronic Neurological, Minneapolis, Minnesota, Apr. 1997.
McEvoy G.,AHFS Drug Information 2004,Bethesda, MD: American Society of Health-System Pharmacists, 2004, pp. 1324-1328 only.
Sitaram B.R., Tsui M., Rawicki H. B., et al., “Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine”,Int. J. Pharm.,153: 13-24, 1997.
United States Pharmacopeia 27thed., Rockville, MD: United States Pharmacopeial Convention, 2004.
USP Dictionary of USAN and International Drug Names 2003, Rockville, MD: United States Pharmacopeial Convention, 2003.
Cardiff, L and Rieck, A.M., “Concentrating on Baclofen,” Australian Journal of Hospital Pharmacy, Feb. 1995, vol. 25, No. 1, pp. 102-103 (abstract).
Trissel Lawrence A.
Zhang Yanping
Board of Regents , The University of Texas System
Huang Gigi
Krass Frederick
Vinson & Elkins LLP
LandOfFree
High concentration baclofen preparations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High concentration baclofen preparations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High concentration baclofen preparations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169556